Median overall survival for African-American men with advanced prostate cancer who are treated with docetaxel (Taxotere) is similar to that of Caucasian men, according to an analysis of pooled data from nine randomized phase III clinical trials.
"Two provocative studies reported at the 2018 ASCO annual meeting provide additional insight into prostate cancer racial disparities in a different group of patients, namely men with advanced prostate cancer who participated in a variety of clinical trials," writes Leonard G. Gomella, MD.
"Many people, including many practicing urologists, are unaware that over the course of the past 40 years, the Urology Care Foundation has supported more than 750 young scientists... with nearly $30 million in funding," writes Brian R. Stork, MD.
Patients with advanced non-clear cell renal cell carcinoma have a high prevalence of germline mutations, including some that could be used to guide therapy.
The finding suggests that, in the setting of a CD117-positive renal tumor biopsy, this modality could reduce patient morbidity and health care costs by avoiding the need for resection in benign cases.
Failure to provide an interpreter incurs legal and regulatory risk.
In this interview, John W. Davis, MD, discusses the advantages and limitations of focal therapy, the ideal candidate, and what current guidelines say about its use.
Imaging with 18F fluciclovine PET/CT (Axumin) tomography identified sites of disease recurrence in a majority of prostate cancer patients with biochemical recurrence and led to changes in treatment course in 59% of men scanned.
Costs could be slashed by $320 million if all men with Gleason scores of 6 or lower pursued initial conservative management, says researcher Justin Trogdon, PhD.
“Our time with patients is very truncated. EMRs actually get in the way of good care. They consume huge amounts of time," says one urologist.